14May 2021
Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer

Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer

Rearrangements of the anaplastic lymphoma kinase (ALK) gene, which encodes for the ALK receptor tyrosine kinase, are detected in ∼5% of patients with non-small-cell lung cancer (NSCLC) with adenocarcinoma histology.1 Crizotinib was the first ALK tyrosine kinase inhibitor (TKI) approved for metastatic, ALK-positive NSCLC and was superior to platinum-based therapy in the first-line setting. However, crizotinib resistance develops due to secondary mutations...

  • #oncology

Like

Save

Share